Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal CEO: Changes At Teva, Sandoz And Viatris Give Us Room To Grow

Chirag Patel Talks International Expansion And Focus On Complex Generics

Executive Summary

Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.

You may also be interested in...



Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies

As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.

Five Things Facing Teva’s New CEO Richard Francis

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears Completion

Viatris has marked an important inflection point in its short life, announcing several more planned divestitures alongside the proposed acquisition of a pair of eyecare companies for up to $750m in cash.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel